Retraction

AAN’s First 21st-Century Position Statement on Ethical Consideration in Dementia Diagnosis and Care

The Editor retracts this editorial¹ at the request of the author because the author does not think that the editorial reflects her views on the topic in light of the FDA’s approval of the drug aducanumab for use in treatment of Alzheimer disease. The FDA approved the drug on June 7, 2021, after the editorial was submitted (February 25, 2021) or accepted in final form by Neurology (March 4, 2021) but before it was published (July 13, 2021.)

REFERENCE


Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.
AAN's First 21st-Century Position Statement on Ethical Consideration in Dementia Diagnosis and Care

Neurology published online August 17, 2021
DOI 10.1212/WNL.0000000000012606

This information is current as of August 17, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/early/2021/08/17/WNL.0000000000012606.citation.full

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise